This application describes embodiments of apparatuses, methods, and systems for the treatment of wounds, specifically to aid in the closure of large wounds, in conjunction with the administration of negative pressure.
Negative pressure wound therapy has been used in the treatment of wounds, and in many cases, it can improve the rate of healing while also removing exudates and other deleterious substances from the wound site.
Amputation of lower and upper extremities is one of the oldest known surgically performed procedures. The vast majority of amputations are performed because of artherosclerosis, which is a symptom of diabetes. Less commonly, serious accidents, cardiovascular disease, or the development of a tumor in a limb can lead to the loss of a limb. Amputation procedures require the removal of the diseased tissue in addition to the cutting and shaping of muscle, therefore a large wound is necessarily created on the patient. Closure of such a wound after the underlying edema has subsided, while minimizing the risk of secondary infections and other complications, then becomes a priority.
Other large or incisional wounds at extremities, either as a result of surgery, trauma, or other conditions, may also require closure. Wound dehiscence of existing wounds is another complication that may arise, possibly due to incomplete underlying fascial closure, or secondary factors such as infection.
Existing negative pressure treatment systems, while permitting eventual wound closure, still require lengthy closure times. Although these may be combined with other tissue securement means, such as sutures or staples, there is also a risk that underlying muscular and fascial tissue is not appropriately re-approximated so as to permit complete wound closure. Further, when foam or other wound fillers are inserted into the wound, the application of negative pressure to the wound and the foam may cause atmospheric pressure to bear down onto the wound, compressing the foam downward and outward against the margins of the wound. This downward compression of the wound filler slows the healing process and slows or prevents the joining of wound margins. Additionally, inflammation of the fascia in the form of certain types of fasciitis can lead to rapid and excessive tissue loss, potentially meriting the need for more advanced negative pressure treatment systems. Further, current negative pressure treatment systems may be inadequate for amputation wounds. Typical negative pressure treatment systems are usually directed to wounds on relatively flat body surfaces, while amputation wounds are located at the end of an extremity, often forming a curved surface. Accordingly, there is a need to provide improved apparatuses, methods, and systems for the treatment and closure of amputation wounds.
Embodiments of the present invention relate to negative pressure wound closure devices, methods, and systems that facilitate closure of a wound. It will be understood by one of skill in the art that the wounds described herein this specification may encompass any wound, and are not limited to a particular location or type of wound. Further, it will be understood by one of skill of art that application of the devices, methods, and systems described herein this specification may be in any manner in relation to negative pressure, and are not limited to the closure of wound or any other particular use. The devices, methods, and systems may operate to reduce the need for repetitive replacement of wound filler material currently employed and can advance the rate of healing. The devices, methods, and systems may be simultaneously used with negative pressure to remove wound fluids.
In certain embodiments, a wound closure device is provided, the device comprises a clamping structure sized and configured to be positioned in or over a wound, the clamping structure having a first end, a second end, a length extending from the first end and the second end, a width transverse to the length extending along a central transverse axis of the clamping structure, and a height transverse to the length and the width. The clamping structure comprises a concave side and a convex side extending the length of the clamping structure from the first end to the second end in parallel or semi-parallel fashion, wherein the concave side is curved or bent concavely with respect to the clamping structure, and the convex side is opposite the concave side and curved or bent convexly with respect to the clamping structure.
A plurality of elongate strips may extend the length of the clamping structure from the first end to the second end, wherein the plurality of elongate strips comprise two outermost elongate strips defining the concave side and the convex side.
A plurality of intervening members may connect the plurality of elongate strips, wherein the plurality of intervening members are configured to pivot relative to the elongate strips to allow the plurality of elongate strips to collapse relative to one another.
A plurality of cells may be provided side-by-side in a horizontal plane parallel to the length and width of the clamping structure, each cell defined by a plurality of walls formed by either the elongate strips or the intervening members, each cell having a top end and a bottom end with an opening extending through the top and bottom ends. The plurality of elongate strips may be configured to increase curvature upon collapse of the plurality of cells and apply a clamping force to the wound.
In certain embodiments, the clamping structure may be at least partially crescent-shaped. The length and width of the clamping structure may be greater than the height of the clamping structure. At least some of the cells may be diamond-shaped.
In certain embodiments, the clamping structure may comprise one or more detachable segments. The one or more detachable segments may comprise attachment elements. The wound closure device may further comprise at least one additional clamping structure.
In certain embodiments, the wound closure device may further comprise a bottom layer of foam configured to conform to concave side of the clamping structure, and/or a top layer of foam configured to conform to the convex side of the clamping structure. The device may further comprise a tissue protection layer.
In certain embodiments, a wound closure device is provided, the device comprising a clamping structure comprising a concave side and a convex side. The clamping structure may be configured to conform to an amputation wound, to apply a closing force to the amputation wound when negative pressure is applied to the clamping structure; and to collapse to a greater extent in a horizontal plane than a vertical plane.
The wound closure device may further comprise a bottom layer of foam attached to the concave side and conforming to the shape of the concave side of the clamping structure; and a top layer of foam attached to the convex side and conforming to the shape of the convex side of the clamping structure.
The clamping structure may be at least partially crescent-shaped. The length and width of the clamping structure may be greater than the height of the structure. The device may further comprise a plurality of cells, wherein at least some of the cells are diamond-shaped. The clamping structure may comprise one or more detachable segments. The one or more detachable segments comprises attachment elements. The device may further comprise at least one additional clamping structure.
In certain embodiments, the wound closure device may further comprise one or more drapes configured to cover the clamping structure and form a seal around the wound. The device may further comprise a suction port configured to supply negative pressure to the wound.
In certain embodiments, the wound closure device may further comprise a negative pressure source configured to supply negative pressure to clamping structure to cause collapse of the plurality of cells and cause the clamping structure to apply the clamping force to the wound.
In certain embodiments, a method of treating a wound is provided, the method comprising: providing a clamping structure of any one of the preceding claims; and placing the clamping structure in or over a wound site wherein the clamping structure is placed so that the concave side of the clamping structure faces the wound and the length of the clamping structure is aligned across the wound opening. The method may further comprise covering the clamping structure with at least one drape sealed to skin surrounding the wound; and applying negative pressure through the at least one drape to the wound via a source of negative pressure, wherein the application of negative pressure causes the clamping structure to collapse. The method may further comprise inserting a tissue protection layer over the wound before placing the clamping structure.
In certain embodiments, a method of closing a wound after limb amputation is provided, the method comprising; providing a clamping structure; inserting a tissue protection layer over the wound; placing the bottom layer of foam over the wound; placing a clamping structure to the wound site wherein the length of the clamping structure is aligned perpendicular to the wound opening; covering the clamping structure with at least one drape sealed to skin surrounding the wound; and applying negative pressure through the at least one drape to the wound via a source of negative pressure, wherein the application of negative pressure causes the clamping structure to collapse.
Other embodiments of an apparatus for use with negative pressure, devices and associated apparatuses are described below.
Embodiments disclosed in this section or elsewhere in this specification relate to apparatuses and methods of treating a wound with reduced pressure, including pump and wound dressing components and apparatuses. The apparatuses and components comprising the wound overlay and packing materials, if any, are sometimes collectively referred to in this section or elsewhere in this specification as dressings.
It will be appreciated that throughout this specification reference is made to a wound. It is to be understood that the term wound is to be broadly construed and encompasses open and closed wounds in which skin is torn, cut or punctured or where trauma causes a contusion, or any other superficial or other conditions or imperfections on the skin of a patient or otherwise that benefit from reduced pressure treatment. A wound is thus broadly defined as any damaged region of tissue where fluid may or may not be produced. Examples of such wounds include, but are not limited to, abdominal wounds or other large or incisional wounds, either as a result of surgery, trauma, sterniotomies, fasciotomies, or other conditions, dehisced wounds, acute wounds, chronic wounds, subacute and dehisced wounds, traumatic wounds, amputation wounds, flaps and skin grafts, lacerations, abrasions, contusions, burns, electrical burns, diabetic ulcers, pressure ulcers, stoma, surgical wounds, trauma and venous ulcers or the like.
As is used in this section or elsewhere in this specification, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below standard atmospheric pressure, which corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects absolute pressure that is X mmHg below 760 mmHg or, in other words, an absolute pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than −X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than ˜60 mmHg).
The negative pressure range for some embodiments of the present disclosure can be approximately −80 mmHg, or between about −10 mmHg and −200 mmHg Note that these pressures are relative to normal ambient atmospheric pressure. Thus, −200 mmHg would be about 560 mmHg in practical terms. In some embodiments, the pressure range can be between about −40 mmHg and −150 mmHg. Alternatively, a pressure range of up to −75 mmHg, up to −80 mmHg or over −80 mmHg can be used. Also in other embodiments a pressure range of below −75 mmHg can be used. Alternatively, a pressure range of over approximately −100 mmHg, or even −150 mmHg, can be supplied by the negative pressure apparatus. In some embodiments, the negative pressure range can be as small as about −20 mmHg or about −25 mmHg, which may be useful to reduce fistulas. In some embodiments of wound closure devices described here, increased wound contraction can lead to increased tissue expansion in the surrounding wound tissue. This effect may be increased by varying the force applied to the tissue, for example by varying the negative pressure applied to the wound over time, possibly in conjunction with increased tensile forces applied to the wound via embodiments of the wound closure devices. In some embodiments, negative pressure may be varied over time for example using a sinusoidal wave, square wave, and/or in synchronization with one or more patient physiological indices (e.g., heartbeat).
Examples of such applications where additional disclosure relating to the preceding descriptions may be found include U.S. Pat. No. 8,235,955, titled “Wound treatment apparatus and method,” issued Aug. 7, 2012 and U.S. Pat. No. 7,753,894, titled “Wound cleansing apparatus with stress,” issued Jul. 13, 2010. Both applications are hereby incorporated by reference in their entirety. Other applications that may contain teachings relevant for use with the embodiments described in this section or elsewhere in this specification may include application Ser. No. 12/886,088, titled “Systems And Methods For Using Negative Pressure Wound Therapy To Manage Open Abdominal Wounds,” filed Sep. 20, 2010, published as US 2011/0213287; application Ser. No. 13/092,042, titled “Wound Dressing And Method Of Use,” filed Apr. 21, 2011, published as US 2011/0282309; and application Ser. No. 13/365,615, titled “Negative Pressure Wound Closure Device,” filed Feb. 3, 2012, published as US 2012/0209227, the entireties of each of which are hereby incorporated by reference. Still more applications that may contain teachings relevant for use with the embodiments described in this specification are application Ser. No. 13/942,493, titled “Negative Pressure Wound Closure Device,” filed Jul. 15, 2013, published as US 2014/0180225; PCT App. No. PCT/US2013/050619, filed Jul. 16, 2013 titled “Negative Pressure Wound Closure Device,” published as WO 2014/014871 A1; PCT App. No. PCT/US2013/050698, filed Jul. 16, 2013 titled “Negative Pressure Wound Closure Device,” published as WO 2014/014922 A1; PCT App. No. PCT/IB2013/01555, titled “Devices and Methods for Treating and Closing Wounds with Negative Pressure,” filed May 5, 2013, published as WO 2013/175309 A1; PCT App. No. PCT/US2014/025059, titled “Negative Pressure Wound Closure Device and Systems and Methods of Use in Treating Wounds with Negative Pressure,” filed Mar. 12, 2014, published as WO 2014/165275 A1; PCT App. No. PCT/GB2014/050746, “Compressible Wound Fillers and Systems and Methods of Use In Treating Wounds With Negative Pressure,” filed Mar. 13, 2014, published as WO 2014/140578 A1; PCT App. No. PCT/US2014/061627, titled “Negative Pressure Wound Closure Device,” filed Oct. 21, 2014, and published as 2016/0287765 A1; and PCT App. No. PCT/US2016/029888, titled “Negative Pressure Wound Closure Device,” filed Apr. 28, 2016, published as WO 2016/176513. The entireties of the aforementioned applications are each hereby incorporated by reference and should be considered part of the present specification.
It will be understood that throughout this specification in some embodiments reference is made to an elongate, elongated or longitudinal strip or strips. It is to be understood that these terms are to be broadly construed and refer in some embodiments to an elongate material having two parallel or substantially parallel faces, where in cross-section a thickness of the material as measured perpendicular to the faces is relatively smaller than a height of the material measured parallel to the faces. While in some embodiments the strips may be constructed from discrete lengths of material, in other embodiments the strips may simply refer to elongate portions of an overall structure having two parallel or substantially parallel faces. The strips in some embodiments have a rectangular or generally rectangular-shaped faces, wherein a length of the face is longer than the height of the face. In some embodiments, the length of the face may be more than 2 times, 4 times, 6 times, 8 time, 10 times, 12 times or greater than the height of the face.
As used in this section or elsewhere in this specification, the term “horizontal,” when referring to a wound, indicates a direction or plane generally parallel to the skin surrounding the wound. The term “vertical,” when referring to a wound, generally refers to a direction extending perpendicular to the horizontal plane. The term “longitudinal,” when referring to a wound, generally refers to a direction in the horizontal plane taken in a direction along which the wound is longest. The term “lateral,” when referring to a wound, generally refers to a direction in the horizontal plane perpendicular to the longitudinal direction. The terms “horizontal,” “vertical,” “longitudinal,” and “lateral” may also be used to describe the stabilizing structures and wound closure devices described throughout this specification. When describing these structures or devices, these terms should not be construed to require that the structures or devices necessarily be placed into a wound in a certain orientation, though in certain embodiments, it may be preferable to do so.
In use, the wound 101 may be prepared and cleaned. In some cases, a non- or minimally-adherent tissue protection layer (not illustrated) may be applied over any exposed internal tissue. The wound packer 102 is then inserted into the wound, and is covered with the drape 104 so as to form a fluid-tight seal. A first end of the conduit 108 is then placed in fluidic communication with the wound, for example via the aperture 106. The second end of the conduit 108 is connected to the pump 110. The pump 110 may then be activated so as to supply negative pressure to the wound 101 and evacuate wound exudate from the wound 101. As will be described in additional detail below and in relation to the embodiments of the foregoing wound closure devices, negative pressure may also aid in promoting closure of the wound 101, for example by approximating opposing wound margins.
Any structure or component disclosed herein this section or elsewhere in the specification may comprise a radiopaque material. A radiopaque material advantageously allows a clinician to more easily find pieces of the wound closure device that may have come loose from the structure and become lost in the wound. Some examples of radiopaque materials include barium sulfate, bismuth trioxide, bismuth subcarbonate, bismuth oxychloride, and tungsten.
All clamping structures described herein this section or elsewhere in the specification may be fashioned to be any size. However, to better accommodate the needs of the clinical environment, in certain embodiments, the clamping structures described herein may be provided in a pack of two sizes, one smaller clamping structure and one larger clamping structure about 1.25 times as larger, about 1.5 times as large, about 1.75 times as large, about 2 times as larger, about 2.5 times as larger, about 3 times as large, about 4 times as large, about 5 times as large, or more than about 5 times as large. In some embodiments, the pack may comprise more than two sizes, such as three sizes, four sizes, five sizes, or more than five sizes. The clamping structures within the pack may be of a variety of sizes in relation to one another such as the ratios described above.
In certain embodiments, the clamping structure 2000 can collapse in any manner described in this section or elsewhere in this specification with or without the application of negative pressure. For example, the clamping structure may collapse significantly more in one plane than in another plane upon application of negative pressure. In some embodiments, the clamping structure is configured to collapse more in a horizontal plane parallel to the length and width of the clamping structure than in a vertical plane perpendicular to the horizontal plane. In embodiments, a particular row of cells may collapse in a first direction, while another row may collapse in the same or an opposing direction. In certain embodiments, the clamping structure may collapse along the width of the clamping structure while remaining relatively rigid along the length and the height of the clamping structure. In certain embodiments, the clamping structure may also transform its overall shape while collapsing, for example, bending along its length or increasing curvature.
The clamping structure may be comprised of any materials described in this section or elsewhere in this specification, including: flexible plastics such as silicone, polyurethane, rigid plastics such as polyvinyl chloride, semi-rigid plastics, semi-flexible plastics, biocompatible materials, composite materials, metals, and foam. In certain embodiments, the clamping structure may comprise a radio opaque material, to more readily allow a clinician to find pieces of the clamping structure within the wound.
Returning to
The clamping structure 2000 further may comprise a concave side wall 2301 defined by the concave side 2101 along the height of the clamping structure, and a convex side wall 2302 defined by the convex side 2102 along the height of the clamping structure. In some embodiments, both of the concave side wall and the convex side wall are parallel with the height and make up the right angle with regard to the horizontal plane. In other embodiments, either of the concave side wall and the convex side wall will be tilted with regard to the height. In some embodiments, the concave side wall and the convex side wall are straight along the height. In other embodiments, the concave side wall and the convex side wall may be curved along the height, so that the clamping structure can be more suitably applied to a contoured object.
As described above, the clamping structure 2000 may comprise a plurality of cells 2004 provided side-by-side, each cell defined by one or more walls, each cell having a top end and a bottom end with an opening extending through the top and bottom ends. As with the other clamping structures described herein this section and elsewhere in the specification, the clamping structure 2000 may be configured to collapse by collapsing one or more cells 2004. In some embodiments, the cells are all of the same approximate shape and size; however, in other embodiments, the cells are of different shapes and sizes.
The elongate strips 2006 may be made from one single material, such as those described elsewhere in the specification, or the elongate strips may be made from multiple materials. For example, elongate strips 2006 may comprise sections of more rigid material and sections of more flexible material. The elongate strips 2006 may be curved along their length so as to facilitate the curve of concave side and/or the convex side the clamping structure 2000. The elongate strips may be curved in the same direction with either the concave side, the convex side, or both. In some embodiments, each of the elongate strips may be curved in the same direction so that they are arranged in parallel or semi-parallel fashion. The arch of the curves of the elongate strips 2006 may vary considerably, with some strips 2006 being highly curved while others are minimally curved or even straight. In some embodiments, the clamping structure may have one elongate strip between the concave side and the convex side. In other embodiments, the clamping structure may have zero, two, three, four or more elongate strips between the concave side and the convex side.
Similarly, the clamping structure 2000 can further comprise a plurality of intervening members 2010 connected to the elongate strips 2006. The intervening members 2010 may all be of a similar shape and size or they may be of a variety of shapes and sizes. The intervening members may be constructed from any material disclosed herein this section or elsewhere in the specification. Further, the intervening members may be constructed from multiple materials.
The clamping structure 2000 and all clamping structures described in this section or elsewhere in this specification can collapse on a variety of timescales in a dynamic fashion. In certain embodiments, the majority of the collapse may occur within the first few minutes upon application of negative pressure. However, after the initial collapse, the clamping structure may continue to collapse at a much slower rate, thereby applying increasing longitudinal tension over a long period of time and drawing the first end and the second together.
In certain embodiments, up to 90% of the collapse of the clamping structure may occur within the first few minutes upon application of negative pressure, while the remaining 10% of the collapse may occur slowly over a period of many minutes, hours, days, weeks, or months. In other embodiments, up to about 80% of the collapse, up to about 70%, up to about 60%, up to about 50%, up to about 40%, up to about 30%, up to about 20%, up to about 10%, or about 0% of the collapse will occur immediately within the first few minutes upon application of negative pressure while the remainder of the collapse occurs at a much slower rate such as over the course of many minutes, hours, days weeks, or months. In other embodiments, the clamping structure can collapse at a variable rate. In some embodiments, the entirety of the collapse occurs at a slowed rate, while in other embodiments the entirety of the collapse occurs almost immediately within the first few minutes. In further embodiments, the collapse can occur at any rate and the rate can vary over time. In certain embodiments, the rate of collapse can be altered in a variable fashion by adding and/or removing portions of the structure or by controlling the application of negative pressure and irrigant fluid.
Any of the clamping structures described herein this section or elsewhere in the specification may be constructed by any suitable means. For example, the clamping structures may be constructed via molding or may be printed directly using 3D printing technology. In certain embodiments, the clamping structures of
In some embodiments, the clamping structure 2000 of
In some embodiments, the clamping structure 2000 of
Applicable to all clamping structures or wound closure devices described in this section or elsewhere in the specification, the clamping structure or wound closure device may be tearable such that the clamping structure may be shaped into any desirable shape. In some embodiments, the clamping structure may be torn at the intersections between intervening members and elongate strips, while in further embodiments, the elongate strips or intervening members may be torn at any suitable position.
To facilitate various types and degree of clamping (for example, maximum clamping) the shape, size, and location of the elongate strips, intervening members, and cells may be determined via various suitable methods.
As illustrated in
As illustrated in
Further, as illustrated in
In some embodiments, a method for generating a clamping structure design may include steps to speed up the initial geometry construction. For example, if all members from left to right in a specific row, as visualized by intervening members 3076 in
One of skill in the art will understand that the detachable sections of the clamping structures of
In embodiments, the clamping structure segments may be cut from the clamping structure 4000 to produce a smaller structure. In certain embodiments, the clamping structure may have pre-cuts along the shape of the segments 4100 and 4200 to allow the segments to be tearable and easily removed by hand from the clamping structure. The detachable segments may be adhered to the remainder of the clamping structure via adhesive, Velcro®, or other suitable adhesive means. In certain embodiments, the removable sections may be held together by the tightness of the structures squeezing together and/or via friction. In some embodiments, magnets and/or suction cups may be used to keep the segments together.
As shown in
In certain embodiments, the detachable segments such as those disclosed above in relation to
In certain embodiments, clamping structures, such as disclosed herein this section or elsewhere in the specification, may collapse in a different manner depending on the shape of the clamping structure. For example, in some embodiments, when the curvature of a clamping structure increases upon collapse of a cell or cells, such transformation may be greater when the difference between the length of the concave side and the convex side is greater. The difference between the length of the concave side and the convex side may be adjusted with installation or removal of detachable segments. For example, in
The clamping structures and/or wound closure devices described in this section or elsewhere in this specification may be used in conjunction with methods or systems for the closure of a wound, for example an amputation wound or wounds at the extremities. In some embodiments, one or more of the clamping structures or wound closure devices of any of the embodiments described in this section or elsewhere in this specification may be placed over a wound. In some embodiments, an organ protection layer may be provided in the wound before placement of the stabilizing structure. In certain embodiments, foam or other porous material may be placed in or on the wound along with the clamping structure or wound closure device, either below, above, or surrounding the clamping structure or wound closure device. Foam or other porous material may also surround the perimeter of the clamping structure or wound closure device. The clamping structure or wound closure device may be configured to collapse in any manner as described in this section or elsewhere in this specification, for example by having a particular size and shape. The clamping structure or wound closure device may further be altered in any manner described in this section or elsewhere in this specification so as to better accommodate the shape of the wound. After placement on the wound, the clamping structure or wound closure device can be sealed by a fluid-tight drape. The fluid-tight drape can comprise a port configured for the application of negative pressure. A source of negative pressure may then be connected to the port and negative pressure may be applied to the wound. The clamping structure or wound closure device may be replaced over time by clamping or wound closure devices of various shapes and sizes as desired to best promote wound healing.
In some embodiments, an optional tissue protection layer (not shown) may be placed over the wound to protect the underlying tissues from the rigors of negative pressure wound therapy or other potential harms. Accordingly, certain embodiments of the wound closure devices comprise a tissue protections layer which may be cut to size to be placed over the wound site 8100. The tissue protection layer can be a material which will not adhere to the wound site or to the exposed viscera in close proximity. Such a tissue protection layer may be constructed from any suitable material such as a biocompatible polymer. For example, organ protection layers manufactured by Smith & Nephew and sold under the brand RENASYS® may act as tissue protection layers and be placed over the wound bed 8100. In further examples, materials such as the fluoropolymer polytetrafluoroethylene (PTFE) may be applicable as these materials are generally non-adherent and used in surgical grafts. In one embodiment, the tissue protection layer is permeable. For example, the tissue protection layer can be provided with openings, such as holes, slits, or channels, to allow the removal of fluids from the wound site 8100 or the transmittal of negative pressure to the wound site 8100. In certain embodiments, the tissue protection layer may comprise a sensor configured to measure pressures in and around the wound. For example, the sensor may be used to measure the level of negative pressure applied to the wound or to measure the pressure on the underlying organs beneath the abdominal wound.
In some embodiments, a bottom layer of foam (not shown) may be optionally placed over the organ protection layer. This bottom layer of foam may extend outward beneath the surface of the wound, and optionally be attached to a clamping structure placed over the foam. This bottom layer of foam may be configured to conform to the concave side of the clamping structure, so that the clamping structure can be properly positioned above the bottom layer of foam. In some embodiments, the bottom layer of foam can extend along the length of the concave side from the first end to the second end, so that the bottom layer of foam provides a cushion between the skin and the clamping structure.
In certain embodiments, such as shown in
In some embodiments, an optional top layer of foam (not shown) may be applied on the convex side of the clamping structure, and optionally be attached to a clamping structure placed below the foam. In embodiments, a layer or layers of foam may be applied around the periphery of the clamping structure. In embodiments, the top layer of foam may be configured to conform to the convex side of the clamping structure, so that it can be properly applied on the clamping structure.
In certain embodiments, a drape may be applied to the top of the top foam, or directly to the top of the clamping structure, thereby forming an air-tight seal over the clamping structure, allowing for the application of negative pressure. Negative pressure may be applied to the clamping structure for any length of time described herein this section or elsewhere in the specification, for example about: 1 hour, 6 hours, 12 hours, 24 hours, 48 hours, or more than 48 hours.
Although this disclosure describes certain embodiments, it will be understood by those skilled in the art that many aspects of the methods and devices shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. Indeed, a wide variety of designs and approaches are possible and are within the scope of this disclosure. No feature, structure, or step disclosed herein is essential or indispensable. Moreover, while illustrative embodiments have been described herein, the scope of any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), substitutions, adaptations and/or alterations as would be appreciated by those in the art based on the present disclosure. While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection.
Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described in this section or elsewhere in this specification unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Furthermore, certain features that are described in this disclosure in the context of separate implementations can also be implemented in combination in a single implementation. Conversely, various features that are described in the context of a single implementation can also be implemented in multiple implementations separately or in any suitable subcombinations. Moreover, although features may be described above as acting in certain combinations, one or more features from a claimed combination can, in some cases, be excised from the combination, and the combination may be claimed as a subcombination or variation of a subcombination.
Moreover, while operations may be depicted in the drawings or described in the specification in a particular order, such operations need not be performed in the particular order shown or in sequential order, or that all operations be performed, to achieve desirable results. Other operations that are not depicted or described can be incorporated in the example methods and processes. For example, one or more additional operations can be performed before, after, simultaneously, or between any of the described operations. Further, the operations may be rearranged or reordered in other implementations. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated and/or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure. Also, the separation of various system components in the implementations described above should not be understood as requiring such separation in all implementations, and it should be understood that the described components and systems can generally be integrated together in a single product or packaged into multiple products.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. Not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.
Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, 0.1 degree, or otherwise.
The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.
This application is a continuation of U.S. application Ser. No. 16/622,248, filed Dec. 12, 2019, which is a U.S. national stage application of International Patent Application No. PCT/EP2018/065397, filed Jun. 11, 2018, which claims priority to U.S. Provisional Application No. 62/518,752 filed on Jun. 13, 2017, which is incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3194239 | Sullivan et al. | Jul 1965 | A |
3789851 | LeVeen | Feb 1974 | A |
4467805 | Fukuda | Aug 1984 | A |
4608041 | Nielsen | Aug 1986 | A |
4699134 | Samuelsen | Oct 1987 | A |
4815468 | Annand | Mar 1989 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5264218 | Rogozinski | Nov 1993 | A |
5376067 | Daneshvar | Dec 1994 | A |
5409472 | Rawlings et al. | Apr 1995 | A |
5415715 | Delage et al. | May 1995 | A |
5423857 | Rosenman et al. | Jun 1995 | A |
5512041 | Bogart | Apr 1996 | A |
5562107 | Lavender et al. | Oct 1996 | A |
5584859 | Brotz | Dec 1996 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5695777 | Donovan et al. | Dec 1997 | A |
6176868 | Detour | Jan 2001 | B1 |
6503208 | Skovlund | Jan 2003 | B1 |
6548727 | Swenson | Apr 2003 | B1 |
6566575 | Stickels et al. | May 2003 | B1 |
6685681 | Lockwood et al. | Feb 2004 | B2 |
6770794 | Fleischmann | Aug 2004 | B2 |
6787682 | Gilman | Sep 2004 | B2 |
6977323 | Swenson | Dec 2005 | B1 |
7004915 | Boynton et al. | Feb 2006 | B2 |
7144390 | Hannigan et al. | Dec 2006 | B1 |
7315183 | Hinterscher | Jan 2008 | B2 |
7351250 | Zamierowski | Apr 2008 | B2 |
7361184 | Joshi | Apr 2008 | B2 |
7438705 | Karpowicz et al. | Oct 2008 | B2 |
7494482 | Orgill et al. | Feb 2009 | B2 |
7615036 | Joshi et al. | Nov 2009 | B2 |
7622629 | Aali | Nov 2009 | B2 |
7625362 | Boehringer et al. | Dec 2009 | B2 |
7683667 | Kim | Mar 2010 | B2 |
7700819 | Ambrosio et al. | Apr 2010 | B2 |
7754937 | Boehringer et al. | Jul 2010 | B2 |
7779625 | Joshi et al. | Aug 2010 | B2 |
7815616 | Boehringer et al. | Oct 2010 | B2 |
7857806 | Karpowicz et al. | Dec 2010 | B2 |
7863495 | Aali | Jan 2011 | B2 |
7892181 | Christensen et al. | Feb 2011 | B2 |
7896856 | Petrosenko et al. | Mar 2011 | B2 |
7909805 | Weston | Mar 2011 | B2 |
7910789 | Sinyagin | Mar 2011 | B2 |
7931774 | Hall et al. | Apr 2011 | B2 |
7942866 | Radl et al. | May 2011 | B2 |
7951124 | Boehringer et al. | May 2011 | B2 |
7964766 | Blott et al. | Jun 2011 | B2 |
7976519 | Bubb et al. | Jul 2011 | B2 |
7976524 | Kudo et al. | Jul 2011 | B2 |
8030534 | Radl et al. | Oct 2011 | B2 |
8057447 | Olson et al. | Nov 2011 | B2 |
8062331 | Zamierowski | Nov 2011 | B2 |
8067662 | Aali et al. | Nov 2011 | B2 |
8070773 | Zamierowski | Dec 2011 | B2 |
8114126 | Heaton et al. | Feb 2012 | B2 |
8123781 | Zamierowski | Feb 2012 | B2 |
8142419 | Heaton et al. | Mar 2012 | B2 |
8172816 | Kazala, Jr. et al. | May 2012 | B2 |
8187237 | Seegert | May 2012 | B2 |
8188331 | Barta et al. | May 2012 | B2 |
8197467 | Heaton et al. | Jun 2012 | B2 |
8207392 | Haggstrom et al. | Jun 2012 | B2 |
8235955 | Blott et al. | Aug 2012 | B2 |
8246590 | Hu et al. | Aug 2012 | B2 |
8257328 | Augustine et al. | Sep 2012 | B2 |
8273105 | Cohen et al. | Sep 2012 | B2 |
8328776 | Kelch et al. | Dec 2012 | B2 |
8337411 | Nishtala et al. | Dec 2012 | B2 |
8353931 | Stopek et al. | Jan 2013 | B2 |
8357131 | Olson | Jan 2013 | B2 |
8376972 | Fleischmann | Feb 2013 | B2 |
8430867 | Robinson et al. | Apr 2013 | B2 |
8447375 | Shuler | May 2013 | B2 |
8454990 | Canada et al. | Jun 2013 | B2 |
8460257 | Locke et al. | Jun 2013 | B2 |
8481804 | Timothy | Jul 2013 | B2 |
8486032 | Seegert et al. | Jul 2013 | B2 |
8500776 | Ebner | Aug 2013 | B2 |
8608776 | Coward et al. | Dec 2013 | B2 |
8632523 | Eriksson et al. | Jan 2014 | B2 |
8663311 | Besselink et al. | Mar 2014 | B2 |
8673992 | Eckstein et al. | Mar 2014 | B2 |
8679080 | Kazala, Jr. et al. | Mar 2014 | B2 |
8679153 | Dennis | Mar 2014 | B2 |
8680360 | Greener et al. | Mar 2014 | B2 |
8708984 | Robinson et al. | Apr 2014 | B2 |
8721629 | Hardman et al. | May 2014 | B2 |
8746662 | Poppe | Jun 2014 | B2 |
8764732 | Hartwell | Jul 2014 | B2 |
8791315 | Lattimore et al. | Jul 2014 | B2 |
8791316 | Greener | Jul 2014 | B2 |
8802916 | Griffey et al. | Aug 2014 | B2 |
8821535 | Greener | Sep 2014 | B2 |
8945030 | Weston | Feb 2015 | B2 |
9044579 | Blott et al. | Jun 2015 | B2 |
9061095 | Adie et al. | Jun 2015 | B2 |
9180231 | Greener | Nov 2015 | B2 |
9408755 | Larsson | Aug 2016 | B2 |
9421132 | Dunn | Aug 2016 | B2 |
9655807 | Locke et al. | May 2017 | B2 |
9849023 | Hall et al. | Dec 2017 | B2 |
10143485 | Locke et al. | Dec 2018 | B2 |
11324876 | Hartwell | May 2022 | B2 |
11872110 | Hartwell | Jan 2024 | B2 |
20010034499 | Sessions et al. | Oct 2001 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020161346 | Lockwood et al. | Oct 2002 | A1 |
20040162512 | Liedtke et al. | Aug 2004 | A1 |
20040267312 | Kanner et al. | Dec 2004 | A1 |
20050142331 | Anderson et al. | Jun 2005 | A1 |
20050267424 | Eriksson et al. | Dec 2005 | A1 |
20060020269 | Cheng | Jan 2006 | A1 |
20060058842 | Wilke et al. | Mar 2006 | A1 |
20060069357 | Marasco | Mar 2006 | A1 |
20060155260 | Blott et al. | Jul 2006 | A1 |
20060217795 | Besselink et al. | Sep 2006 | A1 |
20060271018 | Korf | Nov 2006 | A1 |
20070052144 | Knirck et al. | Mar 2007 | A1 |
20070104941 | Kameda et al. | May 2007 | A1 |
20070118096 | Smith et al. | May 2007 | A1 |
20070123973 | Roth et al. | May 2007 | A1 |
20070129660 | McLeod et al. | Jun 2007 | A1 |
20070149910 | Zocher | Jun 2007 | A1 |
20070185463 | Mulligan | Aug 2007 | A1 |
20070213597 | Wooster | Sep 2007 | A1 |
20070282309 | Bengtson et al. | Dec 2007 | A1 |
20080041401 | Casola et al. | Feb 2008 | A1 |
20080108977 | Heaton et al. | May 2008 | A1 |
20080243096 | Svedman | Oct 2008 | A1 |
20080275409 | Kane et al. | Nov 2008 | A1 |
20080306456 | Riesinger | Dec 2008 | A1 |
20090005716 | Abuzaina et al. | Jan 2009 | A1 |
20090099519 | Kaplan | Apr 2009 | A1 |
20090105670 | Bentley et al. | Apr 2009 | A1 |
20090204423 | DeGheest et al. | Aug 2009 | A1 |
20090312685 | Olsen et al. | Dec 2009 | A1 |
20100022990 | Karpowicz et al. | Jan 2010 | A1 |
20100047324 | Fritz et al. | Feb 2010 | A1 |
20100081983 | Zocher et al. | Apr 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20100150991 | Bernstein | Jun 2010 | A1 |
20100160874 | Robinson et al. | Jun 2010 | A1 |
20100179515 | Swain et al. | Jul 2010 | A1 |
20100198128 | Turnlund et al. | Aug 2010 | A1 |
20100262106 | Hartwell | Oct 2010 | A1 |
20100280468 | Haggstrom et al. | Nov 2010 | A1 |
20100312159 | Aali et al. | Dec 2010 | A1 |
20110021965 | Karp et al. | Jan 2011 | A1 |
20110022082 | Burke et al. | Jan 2011 | A1 |
20110059291 | Boyce et al. | Mar 2011 | A1 |
20110066096 | Svedman | Mar 2011 | A1 |
20110082480 | Viola | Apr 2011 | A1 |
20110110996 | Schoenberger et al. | May 2011 | A1 |
20110112458 | Holm et al. | May 2011 | A1 |
20110178451 | Robinson et al. | Jul 2011 | A1 |
20110224631 | Simmons et al. | Sep 2011 | A1 |
20110224632 | Zimnitsky et al. | Sep 2011 | A1 |
20110224634 | Locke et al. | Sep 2011 | A1 |
20110264138 | Avelar et al. | Oct 2011 | A1 |
20110270301 | Cornet et al. | Nov 2011 | A1 |
20110305736 | Wieland et al. | Dec 2011 | A1 |
20120016321 | Wu et al. | Jan 2012 | A1 |
20120029455 | Perez-Foullerat et al. | Feb 2012 | A1 |
20120059412 | Fleischmann | Mar 2012 | A1 |
20120130327 | Marquez Canada | May 2012 | A1 |
20120136326 | Croizat et al. | May 2012 | A1 |
20120136328 | Johannison et al. | May 2012 | A1 |
20120143113 | Robinson et al. | Jun 2012 | A1 |
20120172926 | Hotter | Jul 2012 | A1 |
20120191132 | Sargeant | Jul 2012 | A1 |
20120209226 | Simmons et al. | Aug 2012 | A1 |
20120209227 | Dunn | Aug 2012 | A1 |
20120253302 | Corley | Oct 2012 | A1 |
20130023842 | Song | Jan 2013 | A1 |
20130150813 | Gordon et al. | Jun 2013 | A1 |
20130190705 | Vess et al. | Jul 2013 | A1 |
20130197457 | Kazala, Jr. et al. | Aug 2013 | A1 |
20130204213 | Heagle et al. | Aug 2013 | A1 |
20130245527 | Croizat et al. | Sep 2013 | A1 |
20130325142 | Hunter et al. | Dec 2013 | A1 |
20130331757 | Belson | Dec 2013 | A1 |
20140094730 | Greener et al. | Apr 2014 | A1 |
20140163415 | Zaiken et al. | Jun 2014 | A1 |
20140180225 | Dunn | Jun 2014 | A1 |
20140249495 | Mumby et al. | Sep 2014 | A1 |
20150065968 | Sealy et al. | Mar 2015 | A1 |
20150119837 | Thompson, Jr. et al. | Apr 2015 | A1 |
20150157758 | Blucher et al. | Jun 2015 | A1 |
20150190288 | Dunn et al. | Jul 2015 | A1 |
20150196431 | Dunn et al. | Jul 2015 | A1 |
20150216732 | Hartwell et al. | Aug 2015 | A1 |
20150320602 | Locke et al. | Nov 2015 | A1 |
20150374561 | Hubbard, Jr. et al. | Dec 2015 | A1 |
20160144085 | Melin et al. | May 2016 | A1 |
20160184496 | Jaecklein et al. | Jun 2016 | A1 |
20170065751 | Toth | Mar 2017 | A1 |
20170281838 | Dunn | Oct 2017 | A1 |
Number | Date | Country |
---|---|---|
2012261793 | Nov 2014 | AU |
2013206230 | May 2016 | AU |
101112326 | Jan 2008 | CN |
101744688 | Jun 2010 | CN |
201519362 | Jul 2010 | CN |
102038575 | May 2011 | CN |
202568632 | Dec 2012 | CN |
103071197 | May 2013 | CN |
203408163 | Jan 2014 | CN |
2949920 | Mar 1981 | DE |
1320342 | Jun 2003 | EP |
2279016 | Feb 2011 | EP |
2567717 | Mar 2013 | EP |
2389794 | Dec 2003 | GB |
2423019 | Aug 2006 | GB |
2489947 | Oct 2012 | GB |
2496310 | May 2013 | GB |
S6257560 | Mar 1987 | JP |
2012105840 | Jun 2012 | JP |
62504 | Apr 2007 | RU |
1818103 | May 1993 | SU |
WO-0185248 | Nov 2001 | WO |
WO-0189392 | Nov 2001 | WO |
WO-0205737 | Jan 2002 | WO |
WO-03003948 | Jan 2003 | WO |
WO-03049598 | Jun 2003 | WO |
WO-2005046761 | May 2005 | WO |
WO-2005105174 | Nov 2005 | WO |
WO-2006046060 | May 2006 | WO |
WO-2008027449 | Mar 2008 | WO |
WO-2008064502 | Jun 2008 | WO |
WO-2008104609 | Sep 2008 | WO |
WO-2009112062 | Sep 2009 | WO |
WO-2010033725 | Mar 2010 | WO |
WO-2010097570 | Sep 2010 | WO |
WO-2011023384 | Mar 2011 | WO |
WO-2012082716 | Jun 2012 | WO |
WO-2012082876 | Jun 2012 | WO |
WO-2012136707 | Oct 2012 | WO |
WO-2012142473 | Oct 2012 | WO |
WO-2013012381 | Jan 2013 | WO |
WO-2013043258 | Mar 2013 | WO |
WO-2013071243 | May 2013 | WO |
WO-2013076450 | May 2013 | WO |
WO-2013079947 | Jun 2013 | WO |
WO-2013175309 | Nov 2013 | WO |
WO-2013175310 | Nov 2013 | WO |
WO-2014013348 | Jan 2014 | WO |
WO-2014140578 | Sep 2014 | WO |
WO-2014158526 | Oct 2014 | WO |
WO-2014165275 | Oct 2014 | WO |
WO-2014178945 | Nov 2014 | WO |
WO-2014194786 | Dec 2014 | WO |
WO-2015008054 | Jan 2015 | WO |
WO-2015061352 | Apr 2015 | WO |
WO-2015109359 | Jul 2015 | WO |
WO-2015110409 | Jul 2015 | WO |
WO-2015110410 | Jul 2015 | WO |
WO-2015169637 | Nov 2015 | WO |
WO-2015193257 | Dec 2015 | WO |
WO-2016018448 | Feb 2016 | WO |
WO-2016176513 | Nov 2016 | WO |
WO-2016179245 | Nov 2016 | WO |
WO-2017106576 | Jun 2017 | WO |
WO-2018038665 | Mar 2018 | WO |
WO-2018041805 | Mar 2018 | WO |
WO-2018044944 | Mar 2018 | WO |
WO-2018044949 | Mar 2018 | WO |
WO-2018085457 | May 2018 | WO |
WO-2018140386 | Aug 2018 | WO |
WO-2018237206 | Dec 2018 | WO |
Entry |
---|
“Definition of 3D Printer,” American Heritage Dictionary of the English Language, Fifth Edition, accessed on Feb. 22, 2018 from URL: https://www.thefreedictionary.com , 2016, 1 page. |
“Definition of Adhere,” The Free Dictionary, accessed on Mar. 23, 2017 from http://www.thefreedictionary.com/adhere, 6 pages. |
“Definition of Oculiform,” Webster's Revised Unabridged Dictionary, accessed from The Free Dictionary on May 30, 2018 from URL: https://www.thefreedictionary.com/Oculiform, 1913, 1 page. |
“Definition of Throughout,” Merriam-Webster Dictionary, accessed on Aug. 29, 2017 from https://www.merriam-webster.com/dictionary/throughout, 11 pages. |
Hougaard, et al., “The Open Abdomen: Temporary Closure with a Modified Negative Pressure Therapy Technique,” International Wound Journal, ISSN 1742-4801, 2014, pp. 13-16. |
International Preliminary Report on Patentability for Application No. PCT/EP2018/065397, mailed on Dec. 26, 2019, 10 pages. |
International Search Report and Written Opinion for Application No. PCT/EP2018/065397, mailed on Jul. 25, 2018, 14 pages. |
Kapischke M., et al., “Self-Fixating Mesh for the Lichtenstein Procedure—a Prestudy,” Langenbeck's Arch Surg, 2010, vol. 395, pp. 317-322. |
Number | Date | Country | |
---|---|---|---|
20240122765 A1 | Apr 2024 | US |
Number | Date | Country | |
---|---|---|---|
62518752 | Jun 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16622248 | US | |
Child | 18397981 | US |